MAR 1 5 2004

FORM PTO-1449

PATENT AND TRADEMARK OFFICE

MENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO.

JJPR-0043

10/727,021

INFORMATION DISCLOSURE CITATION BY APPLICANT

(Use several sheets if necessary)

APPLICANT Lovenberg et al.

FILING DATE December 2, 2003 GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL				ER	DATE INVENTO		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
CH	US	5	5	5	9	1	1	3	September 24, 1996	Schwartz et al.	514	255.05	
CM	US	5	7	0	8	1	7	1	January 13, 1998	Schwartz et al.	Suy		
	ļ	+	├	-	╁	╀	╁	╀				,	
		十	H	\vdash	十	╁	T	t			+		·

FOREIGN PATENT DOCUMENTS

		D	OCI	JME	ENT	N	IMB	ER		DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)
-H	WO	9	3	1	4	0	7	0	July 2	2, 1993	PCT	×	X	
							Τ.	Τ						
					Π	T	T	Τ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	·
	i de la companya de l

EXAMINER

DATE CONSIDERED

20/21/00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





Form PTC	D-1449 Modified	Docket No. JJPR-0043	Application No. 10/727,021						
Cited	ent and Publications by Applicant sheets if necessary)	Applicant. Timothy W. Lovenberg	g, et al.						
	ment of Commerce Trademark Office	Filing Date December 2, 2003	Group Not Yet Assigned						
ОТНЕ	ER DOCUMENTS (Includ	ing Author, Title, Date,	Pertinent Pages, Etc.)						
FH	Class (H3) of Histamine	Receptor", Nature (Londo	mine Release Mediated by a Novel on), 1983, 302,(5911), 832-837						
	Histamine H3 Receptors	on AtT-20 Cells", Agents	ussis Toxin Reduce the Affinity of Actions, 1993, 40(3-4), 129-134						
3	by AtT-20 Cells", Eur. J.	. Pharmacol, 1992, 210(1							
4	Proc. Natl. Acad. Sci. U.	S.A., 1991, 88(2), 429-432							
5	Histamine Receptors", P	harmacol. Rev., 1997, 49							
(Coupled Receptors", Mo	l. Cell. Neurosci, 1991, 2(
7		oning and Functional Exp r Pharmacology, 1999, 55	ression of the Human Histamine 5, 1101-1107						
8	Pollard, H. et al., "A Det		Sapping of Histamine H3 Receptors						
3			NA Encoding the Bovine S.A., 1991, 88(24), 11515-11519						
10	D Backer, M.D. et al., "Ger Pharmacological Charac	Backer, M.D. et al., "Genomic Cloning, Heterologous Expression and Pharmacological Characterization of a Human Histamine H1 Receptor", Biochemic							
4	and Biophysical Research	h Communications, Dece	mber 1993, 197(3), 1601-1608						
FH 11	Phosphinositide Turnove		ceptor Negatively Coupled to cell Line HGT1, the Journal of						
EXAMINER	Fine Home	DATE CON	SIDERED 06/15/05						

Form P	ТО	-1449 Modified	Docket No. JJPR-0043	Application No. 10/727,021						
Cit	ted b	t and Publications y Applicant heets if necessary)	Applicant Timothy W. Lovenberg	, et al.						
		nent of Commerce Trademark Office	Filing Date December 2, 2003	Group Not Yet Assigned						
ОТ	HEF	R DOCUMENTS (Includ	ing Author, Title, Date, I	Pertinent Pages, Etc.)						
FH	12	Hirudin Produced by Sac	charomyces Cerevisiae",	cterization of Recombinant Biochem, 1989, 28, 2941-2949						
	13	Chem, 1989, 264(13), 77	15-7719	t by Fusion to Ubiquitin", J. Biol.						
		in Yeast", J. Biol. Chem.	1990, 265(8), 4189-4192	tional Mammalian Na, K- ATPase						
		Saccharomyces Cerevisia	ae", Gene, 1989, 85(2), 51							
	16	from Teleost Nonspecific 13), 955-965, XP002228	c Cytotoxic Cells", <i>Molect</i> 234	l Receptor Protein Sequenced ular Immunology, 1997, 34, 12-						
	17			on of Sequences Contransfected nentary DNA Gene", J. Mol. Biol.,						
	18	Kitts, et al., "Linearization	on of Baculovirus DNA Er ession Vectors", Nuc. Acid	hances the Recovery of d. Res., 1990, 18(19), 5667-5672						
	19	Predefined Specificity",	Nature, 1975, 256, 495-49							
	20	Leurs, R. et al., "Therapeutic Potential of Histamine H3 Receptor Agonists and Antagonists", Trends in Pharmacological Sciences, Elsevier Trends Journal, 1998, 19(5), 177-184, XP 004121095								
W.	21		cological Characterization of the Human Histamine H2 ed in Chinese Hamster Ovary Cells", British Journal of							
1	22		of Clinical Investigation, 1							
EXAMINER		form It may	DATE CON	SIDERED 06/15/S						

. Form I	PTO-	1449 Modified	Docket No. JJPR-0043	Application No. 10/727,021
. Ci	ited b	and Publications y Applicant heets if necessary)	Applicant Timothy W. Lovenbe	erg, et al.
		ent of Commerce rademark Office	Filing Date December 2, 2003	Group Not Yet Assigned
ro	THER	DOCUMENTS (Includ	ing Author, Title, Date	e, Pertinent Pages, Etc.)
FH	23	Leurs, R. et al., "The His Prog. Drug. Res., 1992,		Target for Developing New Drugs",
	24	McDonnell, et al., "Reco Transcription Unit in Sac 3523	onstitution of the Vitami echaromyces Cerevisiae	n D-Responsive Osteocalcin ", Mol. Cell. Biol., 1989, 9(8), 3517-
	25	Rinas, et al., "Characteri Saccharomyces Cerevisi	ae", Bio/Technology, 19	90, 8(6), 543-546
	26	Fusion Proteins in Sacch	aromyces Cerevisiae",	o Processing of Chimeric Ubiquitin Bio/Technology, 1989, 797), 705-709
	27	Activator Protein of HTI	LV-I", Science, 1987 , 23	
	28	Sleep, et al., "The Secret Saccharomyces Cerevisi 1990, 8, 42-46		lbumin from the Yeast Leader Sequences", BioTechnology,
	29	Tedford, et al., "Develor Derivatives as New High Exper. Therapeutics, 199	n-Affinity Histamine H3 99, 289(2), 1160-1168	nidazol-4-yl] Cyclopropane 3 Receptor Ligands", <i>J. Pharmacol</i> .
	30	Cultured Mouse Cells",		
	31	Directs the Secretion of Biochemistry, 1989, 28(Human Lysozyme in Sa 5), 2728-2732	e Residue in the Signal Sequence that accharomyces Cerevisiae",
	32	Pharmacological Profile	s", <i>JPET</i> , February 200	Receptor Reveals Distinct Species 00, 293(3), 771-778
V	33			terization of Splice Variants of the Journal, 2001, 355, 279-288
EXAMINER		forma Hom	DATE CO	ONSIDERED 06/15/6J

For	m PT	O-1449 Modifie	d	Docket No. JJPR-0043	Application No. 10/727,021		
	Cite	tent and Publications d by Applicant al sheets if necessary	•	Applicant Timothy W. Lovenberg, et al. Filing Date December 2, 2003 Group Not Yet Assigned			
		rtment of Commerce d Trademark Office					
		U.	S. PATENT	DOCUMENTS			
Examiner nitial		Document No.	Date	Name	Class	Subclass	
FH	34	5,817,480	10/06/98	Murry, et al.	435	69	
1	35	5,882,893	03/16/99	Goodearl	435	69	
	36	6,136,559	10/24/00	Lovenberg, et al.	435	69.1	
	37	6,413,743 B1	07/02/02	Lovenberg, et al.	435	69.1	
1	38	6,437,100 B1	08/20/02	Lovenberg, et al.	530	391.1	
					•		
		FORE	ZIGN PATI	ENT DOCUMENTS			
Examiner		Dogwood No.	Date	Country		ranslation	
Initial C 11	39	Document No. EP 1 043 395 A1	10/11/00	Country	YES	NO	
PH PH	40	WO 99/28470	06/10/99	PCT			
F#	40	WO 99120470	00/10/99	rei			
EXAMINER	1	in It-m		DATE CONSIDE	RED 06	115/05	